RATIONALE: Studying the genes expressed in samples of blood and cervix tissue from patients
with a cervical abnormality may help doctors identify biomarkers related to cancer.
PURPOSE: This clinical trial is studying biomarkers in women at high risk for developing
- Assess biomarkers of risk for progressive cervical neoplasia that can distinguish
patients at highest risk for cervical cancers from patients with benign infection.
- Develop a comprehensive list of potential risk biomarkers by examining cervical tissues
of women with normal, human papilloma virus (HPV) infection, precancer, and cancer.
- Measure gene expression profiles to gain an accurate and comprehensive in vivo picture
of cervical neoplasia carcinogenesis.
- Assess the predictive values of candidate biomarkers for key outcomes related to
progression (i.e., HPV persistence, diagnosis of precancer) or nonprogression (i.e.,
OUTLINE: Patients complete a questionnaire on health-related issues, undergo blood
collection and cervix tissue collection along with biopsy for research purposes, and have
photographs of the cervix taken. Cells and secretions from the cervix are also collected and
tested for human papilloma virus infection. The procedure lasts approximately 1 hour.
Information about patients' health and medical records is stored in a data repository.
Patients are followed within 6 weeks after completion of the initial study visit and
periodically thereafter for up to 5 years.
- Abnormal result on most recent pap smear
- Must have been considered for any of the following cervical procedures by a
- Cervical biopsy
- Treatment of a cervical abnormality
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified